Assessing FDA's risk methodology at pharmaceutical manufacturing sites

Warren Adis

International Journal of Business Continuity and Risk Management, 2010, vol. 1, issue 3, 259-270

Abstract: This research analyses the US Food and Drug Administration's (FDA's) risk methodology used for inspecting pharmaceutical manufacturing sites. It reviews the procedures, regulations, and violations specified in FDA warning letters (WLs). In particular it focuses on the time period between 2004-2009, as the FDA transitioned and formalised this new approach to site inspections. One of the principal outcomes of this study is to gauge the FDA's performance and assess its new methodology.

Keywords: FDA risk methodology; pharmaceutical manufacturing sites; CAPA; current good manufacturing practices; cGMP; warning letters; medical devices; FDA assessment; USA; United States; Food and Drug Administration; risk assessment; FDA performance. (search for similar items in EconPapers)
Date: 2010
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.inderscience.com/link.php?id=35689 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ids:ijbcrm:v:1:y:2010:i:3:p:259-270

Access Statistics for this article

More articles in International Journal of Business Continuity and Risk Management from Inderscience Enterprises Ltd
Bibliographic data for series maintained by Sarah Parker ().